MCM
PETX

Moore Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Moore Capital Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300,000
Closed -$1.08M – 422
2019
Q1 		$1.08M Buy
+300,000
New +$1.3M 0.03% 234

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Moore Capital Management's PETX Position: Q2 2019 in Review

Moore Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 300,000 shares — an estimated $1.08M sold.

Moore Capital Management first reported a position in PETX in Q1 2019 and held it in 1 quarter. The position peaked at $1.08M in Q1 2019. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

  • Moore Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Moore Capital Management sold 300,000 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $1.08M.
  • Moore Capital Management first reported a position in Aratana Therapeutics, Inc. in Q1 2019 and held it in 1 quarter.
  • Moore Capital Management's Aratana Therapeutics, Inc. position peaked at $1.08M in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Moore Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.